KLP Kapitalforvaltning AS Makes New $1.19 Million Investment in Inspire Medical Systems, Inc. (NYSE:INSP)

KLP Kapitalforvaltning AS bought a new stake in Inspire Medical Systems, Inc. (NYSE:INSP) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,400 shares of the company’s stock, valued at approximately $1,186,000.

Several other large investors have also made changes to their positions in INSP. First Horizon Advisors Inc. lifted its holdings in Inspire Medical Systems by 885.7% during the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 124 shares during the last quarter. True Wealth Design LLC acquired a new stake in shares of Inspire Medical Systems during the third quarter worth approximately $30,000. Harbour Investments Inc. raised its stake in shares of Inspire Medical Systems by 101.0% in the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock valued at $37,000 after acquiring an additional 99 shares during the last quarter. AlphaQuest LLC boosted its holdings in shares of Inspire Medical Systems by 7,275.0% in the 4th quarter. AlphaQuest LLC now owns 295 shares of the company’s stock worth $55,000 after acquiring an additional 291 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its position in Inspire Medical Systems by 178.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock worth $66,000 after acquiring an additional 229 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling at Inspire Medical Systems

In related news, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the sale, the chief technology officer now owns 10,424 shares in the company, valued at $1,777,187.76. This represents a 5.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now owns 7,259 shares in the company, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,225 shares of company stock valued at $4,806,530. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Price Performance

INSP opened at $156.91 on Friday. Inspire Medical Systems, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $257.40. The company has a market cap of $4.67 billion, a price-to-earnings ratio of 90.70, a price-to-earnings-growth ratio of 2.86 and a beta of 1.48. The firm has a 50 day simple moving average of $179.14 and a 200 day simple moving average of $190.04.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. As a group, analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on INSP. Wells Fargo & Company reduced their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Piper Sandler decreased their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. KeyCorp restated an “overweight” rating and issued a $234.00 price objective (down previously from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Stifel Nicolaus decreased their price target on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a research note on Tuesday, January 21st. Finally, Robert W. Baird lowered their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a report on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $226.70.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.